Objectives: this study is aimed to determine the effect of the ginger-quince compound on dyspepsia of cancerous patients under chemotherapy and radiotherapy treatments at the same time . This study is a Phase 3 clinical trial; a double blind, randomized, and controlled trial with placebo.
Method: inclusion criteria: suffering from cancer; definitely diagnosed by a pathologist; age, 18 year-old or more; under chemotherapy treatments; simultaneous radiotherapy treatments inducing nausea and vomiting such as whole body or upper abdomen RT. Exclusion criteria: Warfarin and Heparin treatment; ASA consuming more than 80 mg; history of blood disorders; history of severe thrombocytopenia; allergy to ginger or consuming it during the past week; gastro-intestinal cancers; having nausea and vomiting induced by factors except chemotherapy or radiotherapy such as CNS tumors, HTN, renal failure or hepatic disorders; gastrointestinal problems like gastric or peptic ulcers; forgetting the use of capsules three consecutive times or more.
Intervention: randomized prescription of standard ginger and quince capsules or placebo three times a day, within 15 minutes of each meal , both starting from 3 days before chemotherapy until completion of radiotherapy period (six weeks). During treatment, the routine anti-vomiting protocol for all patients will be prescribed
Main outcome measures : guring this period nausea , vomiting , bloating , anorexia , poor appetite and postprandial fullness following chemotherapy and radiotherapy will be measured.